
Nephrology Times
Nephrology Times delivers the latest news in nephrological treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Those ≥65 years of age with graft failure had a lower chance of being listed for repeat kidney transplantation.
First, an automated kidney volume segmentation model is used to accurately calculate htTKV.
The prevalence of CKD and cost of screening were the most influential parameters.
A report on outcomes of kidney transplant recipients treated with SGLT2 inhibitors.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
There were no differences seen in adverse events and serious adverse events among trial participants.
A literature review of possible nonpharmacological therapeutic strategies to slow enlargement of cysts in ADPKD.
The predictive power of ESRD progression was high with choline, myo-inositol, and citrate.
The difference in risk between White and Black patients was driven by greater MI risk in Black versus White patients.
There were no statistically significant differences between the two groups in eGFR and proteinuria slopes.
Advertisement
September 2023 Issue
The latest issue of Nephrology Times includes coverage of the 2023 American Transplant Congress as well as the European Renal Association 60th Congress; a review of kidney outcomes in the GRADE study comparing four commonly used classes of glucose-lowering medications added to metformin; and a feature on patterns of prescription of second-line diabetes medications in underserved populations.
Editorials
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Advocacy for improved reimbursement is crucial to ensuring continued access to care.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Telemedicine has emerged as a game-changer in nephrology.
Building a resilient practice
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...